Bernhardt Zeiher

Bernhardt (Bernie) Zeiher, MD, FCCP, FACP, currently serves on the boards of directors for Amylyx Pharmaceuticals, Abeona Therapeutics, and Entrada Therapeutics, focusing on drug development and regulatory affairs within biopharmaceutical companies. Additionally, Bernie operates as a strategic advisor, utilizing extensive expertise gained from past roles including Chief Medical Officer at Astellas Pharma, where leadership spanned early and late-stage development, medical affairs, and regulatory affairs, contributing to six product approvals. Bernie’s career includes significant positions at Pfizer, Eli Lilly and Company, and involvement with multiple industry organizations such as TransCelerate BioPharma and the Biotechnology Innovation Organization. Academic credentials include an MD from Case Western Reserve University and advanced fellowship training in Pulmonary and Critical Care.